Safety of everolimus in patients younger than 3 years of age: Results from EXIST-1, a randomized, controlled clinical trial

Journal of Pediatrics

Volumn 172, Issue , 2016, Pages 151-155.e1

  Jóźwiak, Sergiusz ^a,b   Kotulska, Katarzyna ^b   Berkowitz, Noah ^c   Brechenmacher, Thomas ^d   Franz, David Neal ^e  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS PHARMA K K   (Japan)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; EVEROLIMUS; FIBRINOGEN; IMMUNOSUPPRESSIVE AGENT;

ACINETOBACTER INFECTION; ALKALINE PHOSPHATASE BLOOD LEVEL; APHTHOUS STOMATITIS; ARTICLE; BACTEREMIA; BRONCHITIS; CHILD; CLINICAL ARTICLE; CONVULSION; COUGHING; CYTOPENIA; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR INFECTION; FEMALE; FEVER; HUMAN; HYPERCHOLESTEROLEMIA; INFESTATION; LARYNGITIS; MALE; MOUTH ULCER; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OTITIS MEDIA; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; STOMATITIS; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TUBEROUS SCLEROSIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; ASTROCYTOMA; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; INFANT; MULTICENTER STUDY; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ASTROCYTOMA; CHILD, PRESCHOOL; EVEROLIMUS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; TREATMENT OUTCOME; TUBEROUS SCLEROSIS;

EID: 84973414834     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2016.01.027     Document Type: Article

References (30)

1. H. Northrup, and D.A. Krueger Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference Pediatr Neurol 49 2013 243 254
2. B.A. Staley, E.A. Vail, and E.A. Thiele Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs Pediatrics 127 2011 e117 e125
3. M.E. Adriaensen, C.M. Schaefer-Prokop, T. Stijnen, D.A. Duyndam, B.A. Zonnenberg, and M. Prokop Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature Eur J Neurol 16 2009 691 696
4. C.W. Shepherd, M.R. Gomez, J.T. Lie, and C.S. Crowson Causes of death in patients with tuberous sclerosis Mayo Clin Proc 66 1991 792 796
5. S.L. Dabora, S. Jozwiak, D.N. Franz, P.S. Roberts, A. Nieto, J. Chung, and et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs Am J Hum Genet 68 2001 64 80
6. V. Cuccia, G. Zuccaro, F. Sosa, J. Monges, F. Lubieniecky, and A.L. Taratuto Subependymal giant cell astrocytoma in children with tuberous sclerosis Childs Nerv Syst 19 2003 232 243
7. S. Goh, W. Butler, and E.A. Thiele Subependymal giant cell tumors in tuberous sclerosis complex Neurology 63 2004 1457 1461
8. N. Hussain, A. Curran, D. Pilling, C.L. Malluci, E.J. Ladusans, Z. Alfirevic, and et al. Congenital subependymal giant cell astrocytoma diagnosed on fetal MRI Arch Dis Child 91 2006 520
9. K. Kotulska, J. Borkowska, M. Mandera, M. Roszkowski, E. Jurkiewicz, W. Grajkowska, and et al. Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex Childs Nerv Syst 30 2014 2037 2042
10. P.B. Crino Evolving neurobiology of tuberous sclerosis complex Acta Neuropathol 125 2013 317 332
11. S. de Ribaupierre, G. Dorfmuller, C. Bulteau, M. Fohlen, J.M. Pinard, C. Chiron, and et al. Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery 60 2007 83 89
12. D.A. Krueger, and H. Northrup Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference Pediatr Neurol 49 2013 255 265
13. P. Sun, M. Kohrman, J. Liu, A. Guo, J. Rogerio, and D. Krueger Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis Curr Med Res Opin 28 2012 657 663
14. K. Kotulska, J. Borkowska, M. Roszkowski, M. Mandera, P. Daszkiewicz, K. Drabik, and et al. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients Pediatr Neurol 50 2014 307 312
15. D.N. Franz, E. Belousova, S. Sparagana, E.M. Bebin, M. Frost, R. Kuperman, and et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial Lancet 381 2013 125 132
16. D.N. Franz, E. Belousova, S. Sparagna, E.M. Bebin, M. Frost, R. Kuperman, and et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study Lancet Oncol 15 2014 1513 1520
17. K. Kotulska, J. Borkowska, and S. Jozwiak Possible prevention of tuberous sclerosis complex lesions Pediatrics 132 2013 e239 e242
18. D. Tiberio, D.N. Franz, and J.R. Phillips Regression of a cardiac rhabdomyoma in a patient receiving everolimus Pediatrics 127 2011 e1335 e1337
19. D. Aguilera, R. Flamini, C. Mazewski, M. Schniederjan, L. Hayes, W. Boydston, and et al. Response of subependymal giant cell astrocytoma with spinal cord metastasis to everolimus J Pediatr Hematol Oncol 36 2013 e448 e451
20. A.M. Cappellano, A.A. Senerchia, F. Adolfo, P.M. Paiva, R. Pinho, A. Covic, and et al. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex Childs Nerv Syst 29 2013 2301 2305
21. D. Du Bois, and E.F. Du Bois A formula to estimate the approximate surface area if height and weight be known. 1916 Nutrition 5 1989 303 311
22. Novartis Pharmaceuticals Corporation Afinitor (everolimus tablets for oral administration) Afinitor Disperz (everolimus tablets for oral suspension) [package insert] 2015 Novartis Pharmaceuticals Corporation East Hanover, NJ
23. J. Roth, E.S. Roach, U. Bartels, S. Jóźwiak, M.K. Koenig, H.L. Weiner, and et al. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012 Pediatr Neurol 49 2013 439 444
24. S. Jozwiak, R. Nabbout, P. Curatolo participants of the TSC Consensus meeting for SEGA and Epilepsy Management Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): clinical recommendations Eur J Paediatr Neurol 17 2013 348 352
25. K. Kotulska, D. Chmielewski, J. Borkowska, E. Jurkiewicz, D. Kuczyński, T. Kmieć, and et al. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex Eur J Paediatr Neurol 17 2013 479 485
26. J.J. Bissler, J.C. Kingswood, E. Radzikowska, B.A. Zonnenberg, M. Frost, E. Belousova, and et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial Nephrol Dial Transplant 31 2016 111 119
27. K. Kotulska, E. Jurkiewicz, D. Domanska-Pakiela, W. Grajkowska, M. Mandera, J. Borkowska, and et al. Epilepsy in newborns with tuberous sclerosis complex Eur J Paediatr Neurol 18 2014 714 721
28. C. Porta, S. Osanto, A. Ravaud, M.A. Climent, U. Vaishampayan, D.A. White, and et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma Eur J Cancer 47 2011 1287 1298
29. M. Ferraresso, M. Belingheri, F. Ginevri, L. Murer, L. Dello Strologo, M. Cardillo, and et al. Three-year safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients Pediatr Transplant 18 2014 350 356
30. R. Ganschow, L. Pape, E. Sturm, J. Bauer, M. Melter, P. Gerner, and et al. Growing experience with mTOR inhibitors in pediatric solid organ transplantation Pediatr Transplant 17 2013 694 706